CSS
SLNO

Cubist Systematic Strategies’s Soleno Therapeutics SLNO Stock Holding History

Cubist Systematic Strategies’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-57,006
Closed -$2.29M – 4226
2023
Q4 		$2.29M Buy
+57,006
New +$1.62M 0.01% 1414
2020
Q2 		– Sell
-42
Closed -$2K – 2519
2020
Q1 		$2K Buy
+42
New +$1.79K ﹤0.01% 2111
2019
Q2 		– Sell
-988
Closed -$31K – 2572
2019
Q1 		$31K Buy
+988
New +$26.3K ﹤0.01% 2149

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cubist Systematic Strategies's SLNO Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Soleno Therapeutics (SLNO) in Q1 2024, closing a stake of 57,006 shares — an estimated $2.29M sold.

Cubist Systematic Strategies first reported a position in SLNO in Q1 2019 and held it in 3 quarters. The position peaked at $2.29M in Q4 2023. 98 funds tracked by Wall St. Rank hold SLNO as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining Soleno Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 57,006 Soleno Therapeutics shares in Q1 2024, an estimated $2.29M.
  • Cubist Systematic Strategies first reported a position in Soleno Therapeutics in Q1 2019 and held it in 3 quarters.
  • Cubist Systematic Strategies's Soleno Therapeutics position peaked at $2.29M in Q4 2023.
  • 98 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.